COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

2025 Wells Fargo Healthcare Conference

Thursday, September 4, 2025

Boston, MA

Morgan Stanley 23rd Annual Global Healthcare Conference

Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ET

New York, NY

A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

H.C. Wainwright 27th Annual Global Investment Conference

Fireside Chat Date and Time: Tuesday, September 9, 2025 at 10:30 a.m. ET

New York, NY

A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Cheryl Wheeler

Head of Corporate Communications



EN
28/08/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Third Quarter 2025 Financial Results on November 6...

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio we...

October 23, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces Poster Presentations at the American Academy of Ch...

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences STOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older at the American Academy of Child & Adolescent Psychiatry (AACAP) and Neur...

October 22, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ri...

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing – Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market. “Since its inception, Collegium has remained dedicated to improving the lives of patients with serious medical conditions. That commitment has fueled both our growth and the im...

October 13, 2025 1 EN
Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 17,478 shares at 38.424USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

COLL COLLEGIUM PHARMACEUTICAL INC.
09/03/25 September 3, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare ConferenceThursday, September 4, 2025Boston, MA Morgan Stanley 23rd Annual Global Healthcare ConferenceFireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Comp...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch